Showing 3991-4000 of 4164 results for "".
- Studies Evaluate Effectiveness of Intracameral Omidria for Reducing Postoperative CMEhttps://modernod.com/news/studies-evaluate-effectiveness-of-intracameral-omidria-for-reducing-postoperative-cme/2478216/Recent studies evaluating the use of Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% for the reduction of postoperative clinical cystoid macular edema (CME) incidence show the drug to be safe and effective. Omidria was commercially launched in the US in 2015 as the first
- Sight Sciences Announces Positive Interim Results From Trial of the OMNI Surgical System in Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-positive-interim-results-from-trial-of-the-omni-surgical-system-in-open-angle-glaucoma/2478205/Sight Sciences announced positive 6-month interim safety and efficacy results from a prospective, multicenter, historically controlled clinical trial of the OMNI Surgical System in open-angle glaucoma (OAG). The OMNI Surgical System is currently cleared for use for the delivery of small amounts o
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- Tom Frinzi Joins CorneaGen Board as Executive Chairhttps://modernod.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair. Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T
- Clearside Biomedical Announces FDA Acceptance of Investigational NDA for CLS-AX Administered in Suprachoroidal Spacehttps://modernod.com/news/clearside-biomedical-announces-fda-acceptance-of-investigational-nda-for-cls-ax-administered-in-suprachoroidal-space/2478140/Clearside Biomedical announced that the FDA has accepted its investigational new drug (IND) application for CLS-AX (axitinib injectable suspension), enabling initiation of a phase 1/2a clinical trial of CLS-AX in wet age-related macular degeneration (AMD) patients by the end of 20
- Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Advisory Boardshttps://modernod.com/news/gyroscope-announces-appointment-of-leaders-in-retinal-disease-gene-therapy-and-the-complement-system-to-advisory-boards/2478130/Gyroscope Therapeutics announced the appointment of leading experts in retinal disease, gene therapy, and the complement system to its Clinical and Scientific advisory boards. The newly appointed boards will help guide the development of the company’s lead investigational gene therapy, GT00
- Palatin Technologies Completes Enrollment of Phase 2 Study for Dry Eye Disease Treatment Candidatehttps://modernod.com/news/palatin-technologies-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2478124/Palatin Technologies announced completion of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After delaying enrollment of new patient groups due to the COVID-19 pandemic, Palatin reinitiated enrollment in its PL9643 phase 2 clinical study in subjects
- New Topline Tepezza Data Underscore its Efficacy in Potential for Retreatment in People Living with Thyroid Eye Disease (TED)https://modernod.com/news/new-topline-tepezza-data-underscore-its-efficacy-in-potential-for-retreatment-in-people-living-with-thyroid-eye-disease-ted/2478101/Horizon Therapeutics announced positive topline data from two clinical trials that add to the growing body of evidence supporting the efficacy and safety of Tepezza (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). Tepezza is the first and only medicine approved by the FDA for t
- Roche’s Actemra/RoActemra Fails in Severe COVID-19-Associated Pneumonia Studyhttps://modernod.com/news/roches-actemra-roactemra-fails-in-severe-covid-19-associated-pneumonia-study/2478097/Roche said that a phase 3 study investigating Actemra/RoActemra (tocilizumab) in hospitalized adults with severe COVID-19-associated pneumonia failed to meet its primary endpoint of improved clinical status. The company launched the COVACTA trial in March in order to investigate the anti-IL-6 rec